Patent · US Active

Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide

US8329695B2 · kind B2 · utility

7Cited by

38References

7Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Guenter Linz · Mittelbiberach, DE
Peter Sieger · Mittelbiberach, DE
Rolf Schmid · Gelterkinden, CH
Stefan Goepper · Bad Herrenalb, DE

Key dates

Filing date	Aug 1, 2008
Grant date	Dec 11, 2012
Priority date	—
Expiry date	Mar 12, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention relates to a crystalline form a dihydropteridione derivative, namely a crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.